Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125079 · ClinicalTrials.gov registry record
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
A clinical trial of ARDS (Acute Respiratory Distress Syndrome), sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT07125079 is a study of ARDS (Acute Respiratory Distress Syndrome) that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 36 participants, below the 300-participant average among 4 other ARDS (Acute Respiratory Distress Syndrome) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07125079, a study of ARDS (Acute Respiratory Distress Syndrome), is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune cells and that blockade of this activation may reduce lung damage/injury and help in ARDS management and possibly recovery. To test this hypothesis, the investigators propose to generate an in vitro immune cell model and test a novel (reactive oxygen species) blocking agent PIP-2 on this model. The investigating team will obtain blood of ARDS patients and isolate immune cells (specifically peripheral blood mononuclear cells or PBMC) and monitor the activation of these cells and their blockade by PIP-2. This is entirely an in vitro study.
Conditions Studied
Study Locations (1)
Pennsylvania
- Hospital Of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-11-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07125079
The ClinicalTrials.gov registry entry for NCT07125079 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 4 other ARDS (Acute Respiratory Distress Syndrome) trials with a reported enrollment target (88% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ARDS (Acute Respiratory Distress Syndrome) appearing as the primary indexed condition, and to 0 interventions.
NCT07125079 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07125079 about?
NCT07125079 is a clinical study titled "Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.". Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune ...
What is the current status of trial NCT07125079?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2025-05-20. Estimated completion is 2026-11-20.
What conditions does trial NCT07125079 study?
This clinical trial studies the following conditions: ARDS (Acute Respiratory Distress Syndrome).
Who is sponsoring clinical trial NCT07125079?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07125079 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ARDS (Acute Respiratory Distress Syndrome)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.